Literature DB >> 16806037

[Prognostic factors after surgical resection for hilar cholangiocarcinoma].

G Ramacciato1, N Corigliano, P Mercantini, F Di Benedetto, M Masetti, G Ercolani, A Lauro, N De Ruvo, A-D Pinna.   

Abstract

AIMS: To evaluate short and long-term results in 23 patients resected for hilar cholangiocarcinoma.
METHODS: Between January 2001 and December 2003, 23 patients with hilar cholangiocarcinoma were resected and considered for retrospective analysis. Univariate and multivariate analysis were performed on several clinicopathological variables in order to evaluate the short-term results. Median follow-up was 11 months (interquartile range 2-20 months).
RESULTS: A major liver resection was performed in 19 out of 23 patients (82%): a right hepatectomy extended to segment 4 in 5 patients and a left hepatectomy in 14 patients. Resection of the caudate lobe was performed in 7 patients (30%). No hospital mortality occurred. Overall morbidity rate was 43%. The 1-year survival rate was 63.2% with a median survival of 19 months. Tumor recurrence appeared in 12 patients (52%). Low preoperative albumin level (P=0.006), presence of positive resection margin (P=0.03) and T-stage (P=0.02) were found to be related to a worse median survival. On multivariate analysis, only the preoperative albumin level and the presence of positive margin were confirmed as independent prognostic factors.
CONCLUSION: Aggressive surgical approach remains the only potentially curative therapy for the hilar cholangiocarcinoma. Low preoperative albumin level, presence of positive resection margin and T-stage resulted as factors influencing the prognosis after resection.

Entities:  

Mesh:

Year:  2006        PMID: 16806037     DOI: 10.1016/j.anchir.2006.03.006

Source DB:  PubMed          Journal:  Ann Chir        ISSN: 0003-3944


  3 in total

1.  Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer.

Authors:  Masanori Kobayashi; Tomoyo Sakabe; Hirofumi Abe; Mitsugu Tanii; Hidenori Takahashi; Asako Chiba; Eri Yanagida; Yuta Shibamoto; Masahiro Ogasawara; Shun-ichi Tsujitani; Shigeo Koido; Kazuhiro Nagai; Shigetaka Shimodaira; Masato Okamoto; Yoshikazu Yonemitsu; Noboru Suzuki; Masaki Nagaya
Journal:  J Gastrointest Surg       Date:  2013-07-20       Impact factor: 3.452

2.  [Clinical, epidemiological and therapeutic features of biliary tract cancers: about 20 cases].

Authors:  Ibrahima Ka; Magatte Faye; Papa Saloum Diop; Amadou Bocar Niang Aliou Coly Faye; Jean Marc Ndoye; Babacar Fall
Journal:  Pan Afr Med J       Date:  2018-01-04

3.  Serum albumin predicts survival in patients with hilar cholangiocarcinoma.

Authors:  Abhijeet Waghray; Anastasia Sobotka; Carlos Romero Marrero; Bassam Estfan; Federico Aucejo; K V Narayanan Menon
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.